EXEL logo

Exelixis (EXEL)

Profile

Full Name

Exelixis, Inc.

Ticker Symbol

EXEL

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 17, 2000

Indexes

Not included

Website

http://www.exelixis.com

Employees

1147

Key Details

Price

$43.67(+1.35%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.17B(+18.49% YoY)

Annual EPS

$1.76(+170.77% YoY)

PE ratio

19.85

Next earnings date

Aug 6, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $43.67
    EXEL price is $43.67

    30-Day Relative Volume

    0.81
    EXEL 30-day relative volume is 0.81

    Price Performance

    Price Most recent change

    +1.35%
    EXEL price was up +1.35% on Jun 27, 2025

    Price YTD change

    +31.14%
    EXEL price is up +31.14% since January 1st

    Price 1-year change

    +93.83%
    EXEL price is up +93.83% year-on-year

    Price 3-year change

    +96.53%
    EXEL price is up +96.53% over the past 3 years

    Price Range

    Price All-time high

    $50.50
    EXEL price is currently -13.52% below its historical high of $50.50

    Price 3-year low

    $14.87
    EXEL price is currently +193.68% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market cap

    $11.91B
    EXEL market capitalization is $11.91 billion

    Market cap 3-year change

    +67.1%
    EXEL market capitalization is up +67.1% over the past 3 years

    Market cap All-time high

    $12.62B
    EXEL market capitalization is currently -5.60% below its historical high of $12.62 billion

    Market cap sector rank

    93.45%
    EXEL market capitalization is higher than 93.45% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    -6.38%
    EXEL shares outstanding is down -6.38% year-on-year

    Shares Outstanding 3-Year Change

    -14.98%
    EXEL shares outstanding is down -14.98% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    0.47
    EXEL beta is 0.47

    200-day SMA

    $35.23
    EXEL price is currently +23.96% above its 200-day simple moving average

    50-day SMA

    $40.86
    EXEL price is currently +6.87% above its 50-day simple moving average

    RSI

    56.46
    EXEL 14-day relative strength index is 56.46

    Volume

    0.81
    EXEL 30-day relative volume is 0.81

    ATR

    $1.67
    EXEL average true range is $1.67

    10-day Historical Volatility

    56.04%
    EXEL 10-day historical volatility is 56.04%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $2.17B
    EXEL annual revenue is $2.17 billion

    Revenue Analysts estimate

    $2.33B
    EXEL annual revenue is currently -6.89% lower than the consensus analysts' forecast

    Revenue 1-year change

    +18.49%
    EXEL annual revenue is up +18.49% year-on-year

    Revenue Sector rank

    85.63%
    EXEL annual revenue is higher than 85.63% of companies in Healthcare sector

    EPS

    EPS

    $1.76
    EXEL annual earnings per share is $1.76

    EPS Analysts estimate

    $2.59
    EXEL annual earnings per share is currently -31.95% lower than the consensus analysts' forecast

    EPS 1-year change

    +170.77%
    EXEL annual earnings per share is up +170.77% year-on-year

    EPS Sector rank

    91.76%
    EXEL annual earnings per share is higher than 91.76% of companies in Healthcare sector

    Profit

    Gross profit

    $2.09B
    EXEL annual gross profit is $2.09 billion

    Gross margin

    96.49%
    EXEL annual gross profit margin is 96.49%

    Operating profit

    $689.95M
    EXEL annual operating income is $689.95 million

    Operating margin

    31.81%
    EXEL annual operating profit margin is 31.81%

    Net income

    $521.27M
    EXEL annual net profit is $521.27 million

    Net margin

    24.04%
    EXEL annual net profit margin is 24.04%

    Expenses

    Total expenses

    $1.48B
    EXEL annual total expenses is $1.48 billion

    Operating expenses

    $1.40B
    EXEL annual total operating expenses is $1.40 billion

    Cost of goods sold

    $76.22M
    EXEL annual cost of goods sold is $76.22 million

    Selling, general & administrative expenses

    $492.13M
    EXEL annual SGA is $492.13 million

    Depreciation and amortization

    $28.80M
    EXEL annual depreciation & amortization is $28.80 million

    Interest expense

    -
    EXEL annual interest expense value is unknown

    Income tax

    $160.37M
    EXEL annual income tax is $160.37 million

    EBIT & EBITDA

    EBIT

    $689.95M
    EXEL annual earnings before interest & taxes is $689.95 million

    EBITDA

    $718.75M
    EXEL annual EBITDA is $718.75 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total assets

    $2.95B
    EXEL annual total assets is $2.95 billion

    Non current assets

    $1.48B
    EXEL annual long term assets is $1.48 billion

    Current assets

    $1.47B
    EXEL annual total current assets is $1.47 billion

    Cash and cash equivalents

    $217.37M
    EXEL annual cash & cash equivalents is $217.37 million

    Accounts receivable

    $265.44M
    EXEL annual accounts receivable is $265.44 million

    Inventory

    $22.39M
    EXEL annual inventory is $22.39 million

    Liabilities

    Total liabilities

    $703.49M
    EXEL annual total liabilities is $703.49 million

    Long term liabilities

    $299.72M
    EXEL annual total long term liabilities is $299.72 million

    Current liabilities

    $403.77M
    EXEL annual total current liabilities is $403.77 million

    Accounts payable

    $38.19M
    EXEL annual accounts payable is $38.19 million

    Debt

    Total debt

    $190.82M
    EXEL annual total debt is $190.82 million

    Total debt 1-year change

    +0.46%
    EXEL annual total debt is up +0.46% year-on-year

    Long term debt

    $190.82M
    EXEL annual long term debt is $190.82 million

    Short term debt

    -
    EXEL annual short term debt value is unknown

    Equity & Capital

    Shareholders equity

    $2.24B
    EXEL annual stockholders equity is $2.24 billion

    Book value

    $2.24B
    EXEL annual book value is $2.24 billion

    Retained earnings

    -$98.65M
    EXEL annual retained earnings is -$98.65 million

    Working capital

    $1.06B
    EXEL annual working capital is $1.06 billion

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash from operations

    $699.97M
    EXEL annual cash flow from operations is $699.97 million

    Cash from operations 1-year change

    +110%
    EXEL annual cash flow from operations is up +110% year-on-year

    Cash from investing

    -$116.78M
    EXEL annual cash flow from investing activities is -$116.78 million

    Cash from investing 1-year change

    -333.25%
    EXEL annual cash flow from investing activities is down -333.25% year-on-year

    Cash from financing

    -$628.81M
    EXEL annual cash flow from financing activities is -$628.81 million

    Cash from financing 1-year change

    -15.16%
    EXEL annual cash flow from financing activities is down -15.16% year-on-year

    CAPEX

    CAPEX

    $66.19M
    EXEL annual capital expenditures is $66.19 million

    CAPEX 1-year change

    -59.39%
    EXEL annual capital expenditures is down -59.39% year-on-year

    Free Cash Flow

    Free cash flow

    $633.79M
    EXEL annual free cash flow is $633.79 million

    Free cash flow 1-year change

    +272.04%
    EXEL annual free cash flow is up +272.04% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross margin

    96.49%
    EXEL annual gross profit margin is 96.49%

    Operating margin

    31.81%
    EXEL annual operating profit margin is 31.81%

    Net margin

    24.04%
    EXEL annual net profit margin is 24.04%

    ROA & ROE

    ROA

    17.70%
    EXEL annual return on assets is 17.70%

    ROE

    23.13%
    EXEL annual return on equity is 23.13%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE ratio

    19.85
    EXEL price to earnings ratio is 19.85

    PE ratio Sector rank

    40.65%
    EXEL price to earnings ratio is higher than 40.65% of companies in Healthcare sector

    PB Ratio

    PB ratio

    5.59
    EXEL price to book ratio is 5.59

    PB ratio Sector rank

    82.64%
    EXEL price to book ratio is higher than 82.64% of companies in Healthcare sector

    PS Ratio

    PS ratio

    5.18
    EXEL price to sales ratio is 5.18

    PS ratio Sector rank

    64.64%
    EXEL price to sales ratio is higher than 64.64% of companies in Healthcare sector

    Enterprise value

    Enterprise value

    $11.91B
    EXEL enterprise value is $11.91 billion

    Enterprise value Sector rank

    92.66%
    EXEL enterprise value is higher than 92.66% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    14.11
    EXEL EV/EBITDA is 14.11

    EV/EBITDA Sector rank

    87.73%
    EXEL EV/EBITDA is higher than 87.73% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current ratio

    3.63
    EXEL annual current ratio is 3.63

    Quick ratio

    3.58
    EXEL annual quick ratio is 3.58

    Leverage

    Debt to equity

    0.00
    EXEL annual debt to equity ratio is 0.00

    Interest coverage ratio

    -
    EXEL annual interest coverage ratio value is unknown

    Risk & Stability

    Piotroski F-Score

    9
    EXEL piotroski f-score is 9

    Altman Z-Score

    12.05
    EXEL altman z-score is 12.05

    Analyst ratings

    Recent major analysts updates

    May 15, 25 Citigroup
    Buy
    May 14, 25 Stifel
    Hold
    May 14, 25 RBC Capital
    Outperform
    May 14, 25 Morgan Stanley
    Overweight
    Apr 17, 25 JMP Securities
    Market Outperform
    Mar 27, 25 HC Wainwright & Co.
    Buy
    Mar 13, 25 RBC Capital
    Outperform
    Feb 24, 25 Wells Fargo
    Equal-Weight
    Feb 13, 25 HC Wainwright & Co.
    Buy
    Feb 13, 25 Barclays
    Equal-Weight

    Institutional Ownership

    Screeners with EXEL included

    US stocks
    High Piotroski score stocks
    Most recommended stocks
    Best performing stocks last 3 months
    Best performing stocks last 5 years
    NASDAQ Dividend Calendar
    Stocks above SMA 50
    High revenue growth stocks
    Healthcare sector
    All stocks
    • What is the ticker symbol for Exelixis?
    • Does Exelixis pay dividends?
    • What sector is Exelixis in?
    • What industry is Exelixis in?
    • What country is Exelixis based in?
    • When did Exelixis go public?
    • Is Exelixis in the S&P 500?
    • Is Exelixis in the NASDAQ 100?
    • Is Exelixis in the Dow Jones?
    • When was Exelixis's last earnings report?
    • When does Exelixis report earnings?
    • Should I buy Exelixis stock now?

    What is the ticker symbol for Exelixis?

    The ticker symbol for Exelixis is NASDAQ:EXEL

    Does Exelixis pay dividends?

    No, Exelixis does not pay dividends

    What sector is Exelixis in?

    Exelixis is in the Healthcare sector

    What industry is Exelixis in?

    Exelixis is in the Biotechnology industry

    What country is Exelixis based in?

    Exelixis is headquartered in United States

    When did Exelixis go public?

    Exelixis's initial public offering (IPO) was on April 17, 2000

    Is Exelixis in the S&P 500?

    No, Exelixis is not included in the S&P 500 index

    Is Exelixis in the NASDAQ 100?

    No, Exelixis is not included in the NASDAQ 100 index

    Is Exelixis in the Dow Jones?

    No, Exelixis is not included in the Dow Jones index

    When was Exelixis's last earnings report?

    Exelixis's most recent earnings report was on May 13, 2025

    When does Exelixis report earnings?

    The next expected earnings date for Exelixis is Aug 6, 2025

    Should I buy Exelixis stock now?

    As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
    On this page